Key Points
ONC expects $0.81 EPS and $1.44B revenue on May 6, 2026.
Company shows mixed earnings history with revenue more consistent than EPS.
Brukinsa sales momentum and Tevimbra adoption are critical earnings drivers.
Meyka AI rates ONC B+ but 113x P/E leaves limited room for disappointment.
BeOne Medicines Ltd. (ONC) will report first-quarter earnings on May 6, 2026, at 12:30 PM ET. Analysts expect earnings per share of $0.81 and revenue of $1.44 billion. The oncology company has shown mixed earnings performance recently, beating on EPS in two of the last four quarters while missing on revenue estimates. Investors will focus on Brukinsa and Tevimbra sales momentum, pipeline progress, and guidance for the remainder of 2026. Meyka AI rates ONC with a grade of B+, reflecting solid fundamentals despite valuation concerns.
What Analysts Expect From BeOne Medicines Earnings
The earnings preview shows consensus expectations for ONC’s first-quarter results. Analysts forecast earnings per share of $0.8060 and total revenue of $1.44 billion. These estimates represent a critical test of the company’s ability to sustain growth after recent quarterly volatility.
EPS Estimate Analysis
The $0.81 EPS estimate sits between recent quarterly results. In the previous quarter (February 2026), ONC beat the $1.60 estimate with actual earnings of $0.59 per share, though this represented a significant miss. The company has demonstrated inconsistent earnings delivery, making this quarter’s performance particularly important for rebuilding investor confidence.
Revenue Estimate Context
The $1.44 billion revenue estimate reflects steady expectations for the oncology business. Recent quarters show revenue ranging from $1.31 billion to $1.50 billion, indicating relatively stable top-line performance. This consistency suggests the company’s core drug portfolio continues generating predictable sales despite competitive pressures in the cancer treatment market.
Historical Earnings Performance and Beat/Miss Pattern
BeOne Medicines has delivered inconsistent earnings results over the past four quarters, with a mixed track record on both EPS and revenue estimates. Understanding this pattern helps investors assess the likelihood of a beat or miss on May 6.
Recent EPS Performance
ONC has beaten EPS estimates in two of the last four quarters. In November 2025, the company delivered $1.09 actual EPS against a $0.72 estimate, a significant beat. In August 2025, actual EPS of $0.84 exceeded the $0.48 estimate. However, the February 2026 quarter saw a substantial miss with $0.59 actual versus $1.60 estimated. This volatility suggests earnings surprises remain unpredictable.
Revenue Trends and Consistency
Revenue performance shows more stability than earnings. The company beat revenue estimates in three of the last four quarters. February 2026 delivered $1.50 billion against a $1.42 billion estimate. August 2025 missed with $1.31 billion versus $1.44 billion expected. The pattern suggests revenue estimates may be slightly conservative, favoring potential upside surprises.
Beat/Miss Prediction for May 6
Based on historical patterns, ONC appears more likely to beat on revenue than EPS. The company’s revenue consistency and recent upside surprises suggest the $1.44 billion estimate could be exceeded. However, EPS remains unpredictable due to fluctuating margins and share count changes. Investors should prepare for either outcome on earnings per share.
Key Metrics and What to Watch
Several critical factors will determine whether ONC meets or exceeds expectations on May 6. Investors should monitor specific business drivers and financial metrics that directly impact earnings quality.
Brukinsa and Tevimbra Sales Momentum
Brukinsa (zanubrutinib) remains ONC’s revenue engine, generating over $1.3 billion in annual sales. Investors must watch for quarter-over-quarter growth rates and geographic expansion, particularly in China and Europe. Tevimbra (tislelizumab), the PD-1 monoclonal antibody, represents significant growth potential across multiple cancer indications. Accelerating Tevimbra adoption could drive upside surprises.
Operating Margin Expansion
ONC’s operating margin stands at 8.4% trailing twelve months, reflecting the company’s transition toward profitability. The earnings call should clarify whether the company is achieving operating leverage from its $1.44 billion revenue base. Margin expansion would support higher EPS despite modest revenue growth.
Cash Flow and R&D Investment
Operating cash flow grew 9.2% year-over-year, demonstrating strong cash generation. However, R&D spending represents 40% of revenue, indicating aggressive pipeline investment. Investors should assess whether the company is balancing growth investments with near-term profitability targets.
Analyst Consensus and Guidance
All ten analysts covering ONC rate the stock as a buy, with consensus rating of 4.0. The company’s forward guidance for 2026 will be crucial. Management commentary on pipeline progress, regulatory approvals, and market expansion will influence stock direction post-earnings.
Meyka AI Grade and Investment Perspective
Meyka AI rates ONC with a grade of B+, reflecting a balanced assessment of the company’s financial position and market opportunity. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. The grade is not guaranteed and we are not financial advisors.
What the B+ Grade Means
The B+ rating indicates ONC is a solid performer relative to healthcare and pharmaceutical peers. The company demonstrates strong revenue growth at 44% year-over-year and improving operating income. However, the high valuation multiples present concerns. ONC trades at 113x trailing earnings and 5.96x sales, significantly above sector averages, limiting upside potential.
Valuation Concerns
At $297.14 per share with a $31.75 billion market cap, ONC commands a premium valuation. The price-to-earnings ratio of 120.3 reflects investor expectations for sustained growth. The company must deliver consistent earnings beats and revenue acceleration to justify current valuations. Any disappointment could trigger significant downside.
Growth Trajectory Assessment
ONC’s financial growth metrics show strong momentum. Net income grew 146% year-over-year, and EPS growth reached 103%. Operating cash flow increased 9.2%, supporting the company’s ability to fund R&D and return capital. These metrics support the B+ rating despite valuation headwinds. Investors should monitor whether growth rates sustain through 2026.
Final Thoughts
BeOne Medicines reports May 6 earnings with high expectations and a 113x P/E valuation that leaves little room for error. Analysts forecast $0.81 EPS and $1.44 billion revenue. The company historically beats revenue more often than earnings. Key drivers include Brukinsa sales, Tevimbra adoption, and 2026 guidance. A revenue beat with positive pipeline commentary could drive gains, while an earnings miss risks sharp declines given the premium valuation.
FAQs
What are analysts expecting from ONC’s May 6 earnings report?
Analysts expect BeOne Medicines to report earnings per share of $0.81 and revenue of $1.44 billion. These estimates reflect expectations for steady performance from the company’s oncology drug portfolio, particularly Brukinsa and Tevimbra sales.
Has ONC beaten or missed earnings estimates recently?
ONC has delivered mixed results. The company beat EPS estimates in two of the last four quarters but missed significantly in February 2026 with $0.59 actual versus $1.60 estimated. Revenue performance is more consistent, with three beats in four quarters.
What should investors watch during the earnings call?
Key focus areas include Brukinsa and Tevimbra sales growth, operating margin expansion, R&D spending efficiency, and management guidance for 2026. Geographic expansion in China and Europe and pipeline progress on new cancer indications are critical drivers.
Why does ONC trade at such a high valuation multiple?
ONC’s 113x P/E ratio reflects investor expectations for sustained growth in oncology treatments. The company’s 44% revenue growth and 146% net income growth justify premium valuations, but any earnings disappointment could trigger sharp downside.
What does Meyka AI’s B+ grade mean for ONC investors?
The B+ grade indicates ONC is a solid performer relative to healthcare peers with strong growth metrics. However, the high valuation leaves limited margin for error. The grade factors in S&P 500 comparison, sector performance, financial growth, and analyst consensus.
Disclaimer:
Stock markets involve risks. This content is for informational purposes only. Earnings estimates are analyst projections and not guarantees of actual results. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.
What brings you to Meyka?
Pick what interests you most and we will get you started.
I'm here to read news
Find more articles like this one
I'm here to research stocks
Ask Meyka Analyst about any stock
I'm here to track my Portfolio
Get daily updates and alerts (coming March 2026)